Total Funding
78
24
Total FundingGrant raised
Growth Score 78 in past quarter
-4 pts
Heat Score 24 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
489341
Metabolomx is a biotech company that develops systems for the identification of lung cancer from breath.
- Paul Rhodes: Founder and CEO
- Ray Martino: Founder and COO
About the Company
Metabolomx, has developed technology enabling the identification of lung cancer from breath. Using the first generation of our breath analysis system, the Cleveland Clinic announced the results of a 237 subject trial at the American College of Chest Physicians conference in November 2010, reporting 81%, accuracy of lung cancer detection, comparable
to CT scan, the present gold standard. This study, further reported that lung cancer subtype (small cell, adenocarcinoma, and squamous cell) is identified by the breath exam (manuscript attached). The Cleveland Clinic has now commenced testing of the current generation Metabolomx sensor, over 100x more sensitive than the version used in the study in press.
